Replies to post #151797 on Vivos Inc (RDGL)

[splintered sunlight]

Excellent points.

[anderson800]

At the end of 2020 and into 2021 when the possibility of breakthrough technology designation was on the table our volume was 10-70 million shares per week. At that time Vivos had less exposure than they have now. The volume will come when the news is there.

[SC8]

Problem is right now RDGL is much more iffy and much less whenish. Agree need substantive news, but has to be both positive and substantive. You mention FDA approval, which may be years away and very iffy, so that doesn't attract buyers. FDA approving human trials is more likely (but not certain) in next several months, but been hearing that for years now, so gets ignored like the boy who cried wolf. Likewise with IsoPet revenue: has to be on demonstrable path to profitability to value that business. Right now Isopet business is worthless.

Is what it is. Nothing to turn page at moment. Looking forward to post Oct. 17 meeting update.